Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Altimmune Inc (ALT)

Altimmune Inc (ALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 554,056
  • Shares Outstanding, K 104,342
  • Annual Sales, $ 20 K
  • Annual Income, $ -95,060 K
  • EBIT $ -90 M
  • EBITDA $ -94 M
  • 60-Month Beta -0.03
  • Price/Sales 26,659.38
  • Price/Cash Flow N/A
  • Price/Book 2.63

Options Overview Details

View History
  • Implied Volatility 204.58% (+43.81%)
  • Historical Volatility 61.25%
  • IV Percentile 86%
  • IV Rank 40.87%
  • IV High 432.33% on 11/06/25
  • IV Low 47.16% on 08/20/25
  • Expected Move (DTE 6) 0.66 (12.65%)
  • Put/Call Vol Ratio 0.33
  • Today's Volume 10,265
  • Volume Avg (30-Day) 9,359
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 248,714
  • Open Int (30-Day) 237,132
  • Expected Range 4.58 to 5.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.25
  • Number of Estimates 5
  • High Estimate -0.23
  • Low Estimate -0.30
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +24.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.76 +39.36%
on 11/06/25
5.46 -4.03%
on 12/04/25
+1.49 (+39.73%)
since 11/05/25
3-Month
3.54 +48.02%
on 09/15/25
5.46 -4.03%
on 12/04/25
+1.46 (+38.62%)
since 09/05/25
52-Week
2.90 +80.69%
on 06/26/25
9.95 -47.34%
on 12/10/24
-3.90 (-42.67%)
since 12/05/24

Most Recent Stories

More News
Altimmune Announces CEO Transition and Succession Plan

Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer Transition follows seven years of strong leadership by Dr. Garg GAITHERSBURG, Md., Dec. 01,...

ALT : 5.24 (-1.32%)
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic...

ALT : 5.24 (-1.32%)
Metabolic Reset: Cell Therapies and Novel Drugs Reshape Chronic Disease Market

VANCOUVER – Baystreet.ca News Commentary – The metabolic disorder therapeutics market projects growth to $120.7 billion by 2030 as biotechnology firms pioneer organ-level treatments addressing diabetes,...

AVAI : 0.2875 (-2.58%)
TNDM : 20.92 (+1.01%)
CRNX : 46.67 (-1.58%)
MDGL : 577.30 (-1.52%)
ALT : 5.24 (-1.32%)
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

24-week data demonstrated significant MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile Significant improvements observed in secondary...

ALT : 5.24 (-1.32%)
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement Pemvidutide demonstrated significant reductions in...

ALT : 5.24 (-1.32%)
Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

48-week Data from Phase 2b IMPACT Trial of Pemvidutide in MASH Expected Before Year End End-of-Phase 2 Meeting with FDA for MASH Program Scheduled in Fourth Quarter Executive Leadership Strengthened...

ALT : 5.24 (-1.32%)
Altimmune to Participate in Two Upcoming Investor Conferences

GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic...

ALT : 5.24 (-1.32%)
Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Enrollment completed ahead of schedule, underscoring strong interest from patient community in a potential new therapeutic option On track to complete the 24-week treatment period and announce topline...

ALT : 5.24 (-1.32%)
Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic...

ALT : 5.24 (-1.32%)
Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

Oral presentation to highlight 24-week efficacy and safety data Poster to feature results of AI-based analyses of liver fibrosis reduction GAITHERSBURG, Md., Oct. 20, 2025 (GLOBE NEWSWIRE) --...

ALT : 5.24 (-1.32%)

Business Summary

Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 5.64
2nd Resistance Point 5.54
1st Resistance Point 5.39
Last Price 5.24
1st Support Level 5.14
2nd Support Level 5.04
3rd Support Level 4.89

See More

52-Week High 9.95
Fibonacci 61.8% 7.26
Fibonacci 50% 6.43
Fibonacci 38.2% 5.59
Last Price 5.24
52-Week Low 2.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar